Oragenics' SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants

Stock Information for Oragenics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oragenics Inc.

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
Oragenics, Inc. Files 10K and Provides Company Update
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
Oragenics Announces Closing of Public Offering
Oragenics Announces Pricing of Public Offering
Oragenics Announces Proposed Public Offering
Oragenics, Inc. Announces Leadership Transition

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.